Zhengye Biotechnology Holding
ZYBT
8 hedge funds and large institutions have $113K invested in Zhengye Biotechnology Holding in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0.23% less ownership
Funds ownership: 0.49% → 0.26% (-0.23%)
27% less funds holding
Funds holding: 11 → 8 (-3)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
57% less capital invested
Capital invested by funds: $265K → $113K (-$152K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.53K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$793 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$39.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35.2K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$28K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$14.2K |
| 5 |
Morgan Stanley
New York
|
-$1.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $41.3K | -$14.2K | -15,140 | -26% |
|
|
WG
2
Winton Group
London,
United Kingdom
| $31.2K | -$28K | -29,908 | -47% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $27.2K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $7.51K | -$1.01K | -1,079 | -12% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.59K | +$2.53K | +2,705 | +123% |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$793 | +847 | +221% |
|
|
7
Morgan Stanley
New York
| $244 | -$1.26K | -1,346 | -84% |
|
|
CIAM
8
Caitong International Asset Management
Hong Kong
| $1 | – | – | – |
|
|
9
Invesco
Atlanta,
Georgia
| – | -$39.9K | -34,688 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$35.2K | -30,576 | Closed |
|
11
JP Morgan Chase
New York
| – | -$526 | -457 | Closed |
|
ZYBT Hedge Fund Activity: Q1 2026 in Review
8 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Zhengye Biotechnology Holding (ZYBT) for Q1 2026, worth a combined $113K — down 57% from $265K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ZYBT and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.53K. The largest seller was Invesco, exiting entirely with an estimated $39.9K sold.
- 8 institutional investors held Zhengye Biotechnology Holding (ZYBT) as of Q1 2026, down from 11 in Q4 2025.
- Funds reported $113K of Zhengye Biotechnology Holding stock for Q1 2026, down 57% quarter-over-quarter.
- 0 funds opened new Zhengye Biotechnology Holding positions in Q1 2026 and 3 closed out, a net change of -3 holders.
- The largest Zhengye Biotechnology Holding buyer in Q1 2026 was Tower Research Capital (TRC), an estimated $2.53K added.
- The largest Zhengye Biotechnology Holding seller in Q1 2026 was Invesco, an estimated $39.9K sold.
Based on aggregated 13F filings for Q1 2026.